Kenneth Kernen, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $572,931 of the $910,213 with a category attached, or 62.9%. It is spread thinly across 55 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2019 at $224,487 and has fallen 54.7% since, to $101,769 in 2025. Among urology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,109 payments — averaging $820.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$207K
- Bayer$155K
- Johnson & Johnson$146K
- AstraZeneca$66K
- Pfizer$55K
- Siemens Medical Solutions USA, Inc.$36K
- plus $246K from 49 others
Across 290 payments — averaging $8669.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$1.8M
- Dendreon Pharmaceuticals LLC$292K
- Astellas Pharma Global Development$131K
- Pfizer$121K
- Veru Inc.$108K
- Bayer$25K
- plus $39K from 4 others
What the payments were for
- Consulting fees$208,68323%
- Speaking & faculty fees$572,93163%
- Travel & lodging$101,15911%
- Food & beverage$19,7132%
- Education$7,7261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$218,988
- Erleada$112,724
- Nubeqa$96,228
- ORGOVYX$68,746
- LYNPARZA$67,786
- Xofigo$62,069
- iTIND System$36,052
- RYBREVANT$31,046
- CARVYKTI$31,046
- AKEEGA$22,035
- Rubraca$21,515
- TALZENNA$20,651
- PYLARIFY$17,252
- PROVENGE$15,509
- KEYTRUDA$14,865
- Olympus Resection Disposables$8,999
- FOUNDATIONACT$4,003
- FOUNDATIONFOCUS$4,003
- FOUNDATIONONE CDX$4,003
- FOUNDATIONONE HEME$4,003
How this compares
$910,213 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 107 | $1,440,575 |
| ErleadaApalutamide | 27 | $384,954 |
| OrgovyxRelugolix | 92 | $232,563 |
| NubeqaDarolutamide | 12 | $162,117 |
| Abiraterone Acetate | 86 | $138,293 |
| GemtesaVibegron | 116 | $121,619 |
| MyrbetriqMirabegron | 98 | $107,618 |
| Finasteride | 1,893 | $35,658 |
| Tolterodine Tartrate | 324 | $28,937 |
| Mirabegron ErMirabegron | 35 | $22,909 |
| Tamsulosin Hcl | 1,012 | $22,868 |
| Dutasteride | 411 | $18,871 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 411 | $13,163 |
| Testosterone | 107 | $11,352 |
| Tolterodine Tartrate ErTolterodine Tartrate | 83 | $8,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $206,902 | $1,548,193205 claims |
| Johnson & JohnsonErleada | $145,855 | $384,95427 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $33,756 | $354,182208 claims |
| BayerNubeqa | $154,765 | $162,11712 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,240 | $138,29386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.
Other urology in Troy
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
- Aram LoebDetroit$112K
- Marcus JamilPlymouth$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.